608 related articles for article (PubMed ID: 27480166)
1. Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence.
Lim JS; Soo RA
Ther Adv Respir Dis; 2016 Oct; 10(5):444-54. PubMed ID: 27480166
[TBL] [Abstract][Full Text] [Related]
2. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab: a review in advanced squamous non-small cell lung cancer.
Keating GM
Drugs; 2015 Nov; 75(16):1925-34. PubMed ID: 26514815
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Brahmer J; Reckamp KL; Baas P; Crinò L; Eberhardt WE; Poddubskaya E; Antonia S; Pluzanski A; Vokes EE; Holgado E; Waterhouse D; Ready N; Gainor J; Arén Frontera O; Havel L; Steins M; Garassino MC; Aerts JG; Domine M; Paz-Ares L; Reck M; Baudelet C; Harbison CT; Lestini B; Spigel DR
N Engl J Med; 2015 Jul; 373(2):123-35. PubMed ID: 26028407
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
Horn L; Spigel DR; Vokes EE; Holgado E; Ready N; Steins M; Poddubskaya E; Borghaei H; Felip E; Paz-Ares L; Pluzanski A; Reckamp KL; Burgio MA; Kohlhäeufl M; Waterhouse D; Barlesi F; Antonia S; Arrieta O; Fayette J; Crinò L; Rizvi N; Reck M; Hellmann MD; Geese WJ; Li A; Blackwood-Chirchir A; Healey D; Brahmer J; Eberhardt WEE
J Clin Oncol; 2017 Dec; 35(35):3924-3933. PubMed ID: 29023213
[TBL] [Abstract][Full Text] [Related]
6. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Hanna N; Johnson D; Temin S; Baker S; Brahmer J; Ellis PM; Giaccone G; Hesketh PJ; Jaiyesimi I; Leighl NB; Riely GJ; Schiller JH; Schneider BJ; Smith TJ; Tashbar J; Biermann WA; Masters G
J Clin Oncol; 2017 Oct; 35(30):3484-3515. PubMed ID: 28806116
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Gettinger S; Rizvi NA; Chow LQ; Borghaei H; Brahmer J; Ready N; Gerber DE; Shepherd FA; Antonia S; Goldman JW; Juergens RA; Laurie SA; Nathan FE; Shen Y; Harbison CT; Hellmann MD
J Clin Oncol; 2016 Sep; 34(25):2980-7. PubMed ID: 27354485
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer.
Rounds A; Kolesar J
Am J Health Syst Pharm; 2015 Nov; 72(21):1851-5. PubMed ID: 26490818
[TBL] [Abstract][Full Text] [Related]
9. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
[TBL] [Abstract][Full Text] [Related]
10. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Rizvi NA; Mazières J; Planchard D; Stinchcombe TE; Dy GK; Antonia SJ; Horn L; Lena H; Minenza E; Mennecier B; Otterson GA; Campos LT; Gandara DR; Levy BP; Nair SG; Zalcman G; Wolf J; Souquet PJ; Baldini E; Cappuzzo F; Chouaid C; Dowlati A; Sanborn R; Lopez-Chavez A; Grohe C; Huber RM; Harbison CT; Baudelet C; Lestini BJ; Ramalingam SS
Lancet Oncol; 2015 Mar; 16(3):257-65. PubMed ID: 25704439
[TBL] [Abstract][Full Text] [Related]
11. The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer.
Tanvetyanon T; Creelan BC; Antonia SJ
Expert Rev Anticancer Ther; 2016 Sep; 16(9):903-10. PubMed ID: 27488231
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.
Vokes EE; Ready N; Felip E; Horn L; Burgio MA; Antonia SJ; Arén Frontera O; Gettinger S; Holgado E; Spigel D; Waterhouse D; Domine M; Garassino M; Chow LQM; Blumenschein G; Barlesi F; Coudert B; Gainor J; Arrieta O; Brahmer J; Butts C; Steins M; Geese WJ; Li A; Healey D; Crinò L
Ann Oncol; 2018 Apr; 29(4):959-965. PubMed ID: 29408986
[TBL] [Abstract][Full Text] [Related]
13. The safety of nivolumab for the treatment of advanced non-small cell lung cancer.
Metro G; Ricciuti B; Brambilla M; Baglivo S; Soli I; Minenza E; Leonardi GC; D'arpino A; Colabrese D; Tazza M; Zicari D; Minotti V; Chiari R
Expert Opin Drug Saf; 2017 Jan; 16(1):101-109. PubMed ID: 27910704
[TBL] [Abstract][Full Text] [Related]
14. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
Hoffner B; Leighl NB; Davies M
Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer.
Keating GM
Drugs; 2016 Jun; 76(9):969-78. PubMed ID: 27189706
[TBL] [Abstract][Full Text] [Related]
16. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Borghaei H; Gettinger S; Vokes EE; Chow LQM; Burgio MA; de Castro Carpeno J; Pluzanski A; Arrieta O; Frontera OA; Chiari R; Butts C; Wójcik-Tomaszewska J; Coudert B; Garassino MC; Ready N; Felip E; García MA; Waterhouse D; Domine M; Barlesi F; Antonia S; Wohlleber M; Gerber DE; Czyzewicz G; Spigel DR; Crino L; Eberhardt WEE; Li A; Marimuthu S; Brahmer J
J Clin Oncol; 2021 Mar; 39(7):723-733. PubMed ID: 33449799
[TBL] [Abstract][Full Text] [Related]
17. Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.
Melosky B; Chu Q; Juergens R; Leighl N; McLeod D; Hirsh V
J Clin Oncol; 2016 May; 34(14):1676-88. PubMed ID: 26884577
[TBL] [Abstract][Full Text] [Related]
18. Best practice in the treatment of advanced squamous cell lung cancer.
Ang YL; Tan HL; Soo RA
Ther Adv Respir Dis; 2015 Oct; 9(5):224-35. PubMed ID: 25902866
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer.
Hida T; Nishio M; Nogami N; Ohe Y; Nokihara H; Sakai H; Satouchi M; Nakagawa K; Takenoyama M; Isobe H; Fujita S; Tanaka H; Minato K; Takahashi T; Maemondo M; Takeda K; Saka H; Goto K; Atagi S; Hirashima T; Sumiyoshi N; Tamura T
Cancer Sci; 2017 May; 108(5):1000-1006. PubMed ID: 28266091
[TBL] [Abstract][Full Text] [Related]
20. A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study.
Hayashi H; Chiba Y; Sakai K; Fujita T; Yoshioka H; Sakai D; Kitagawa C; Naito T; Takeda K; Okamoto I; Mitsudomi T; Kawakami Y; Nishio K; Nakamura S; Yamamoto N; Nakagawa K
Clin Lung Cancer; 2017 Nov; 18(6):719-723. PubMed ID: 28623122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
